3 months The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill Benzinga      

Here’s a roundup of top developments in the biotech space over the last 24 hours.

Stocks In Focus

Lexicon Clinches Deal to Secure $150M Debt Financing For Supporting Potential Launch Of Heart Failure Drug

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) announced an agreement relating to a loan facility with Oxford Finance for up to $150 million in borrowing capacity. The funding will primarily support commercial preparations and the potential launch of sotagliflozin in heart failure, it added.

Late last month, the company voluntarily withdrew the regulatory application filed with the U.S. Food and Drug Administration for sotagliflozin to correct what it claimed to be a technical flaw. The company also said it targets a resubmission in the second quarter.

The stock was adding 4.55% to $2.30 in premarket trading.

Click here to access Benzinga’s FDA Calendar

Moderna Files For Expanding Authorization For Second Booster Dose Of COVID-19 Vaccine

Moderna, Inc. (NASDAQ: MRNA) said it has submitted a request to the FDA for an amendment to the emergency use authorization to allow for a fourth dose of its COVID-19 vaccine in adults 18 years of …

Full story available on Benzinga.com